Quarterly report pursuant to Section 13 or 15(d)

MEZZANINE EQUITY (Details Narrative)

v3.21.1
MEZZANINE EQUITY (Details Narrative) - USD ($)
 1 Months Ended 3 Months Ended
Feb. 29, 2020
Mar. 31, 2021
Feb. 29, 2020
Mar. 31, 2021
Mar. 31, 2020
Entity Listings [Line Items]          
Stock Issued During Period, Value, New Issues      
Proceeds from Issuance or Sale of Equity   $ 23,000,000.0      
Payments for Construction in Process   $ 7,800,000      
Company owned and managed facilities during period       $ 2.0  
Targeted acquisition commitment, description   The balance of the committed facility of up to an additional $23.0 million is intended to fund the Company’s specific targeted acquisitions provided such acquisitions are contracted in 2021 and consummated, including obtaining the necessary regulatory approvals, no later than the end of 2022.      
Maximum [Member]          
Entity Listings [Line Items]          
Class of Warrant or Right, Exercise Price of Warrants or Rights   $ 5.50   $ 5.50 $ 5.50
Minimum [Member]          
Entity Listings [Line Items]          
Class of Warrant or Right, Exercise Price of Warrants or Rights   $ 0.25   0.25  
Hadron Healthcare Master Fund [Member] | Warrants [Member]          
Entity Listings [Line Items]          
Stock Issued During Period, Shares, New Issues   6,216,216      
Class of Warrant or Right, Exercise Price of Warrants or Rights   $ 1.087   $ 1.087  
Fair value of warrants issuance       $ 9,500,000  
Stock issuance costs   $ 387,000      
Hadron Healthcare Master Fund [Member] | Maximum [Member] | Warrants [Member]          
Entity Listings [Line Items]          
Class of Warrant or Right, Number of Securities Called by Warrants or Rights   15,540,540   15,540,540  
3M Note [Member]          
Entity Listings [Line Items]          
Repayments of Debt and Lease Obligation   $ 15,200,000      
Series B Convertible Preferred Stock [Member] | Volume Weighted Average Price of Common Stock [Member]          
Entity Listings [Line Items]          
Preferred stock, conversion price $ 4.00   $ 4.00    
Number of trading days, description     least twenty consecutive trading days    
Series B preferred stock conversion price, description If the sixty-day VWAP is greater than $0.50 per share, the Company shall have the option   If the sixty-day VWAP is less than or equal to $0.50 per share, the Company shall have the option to (i) convert all shares of Series B convertible preferred stock into common stock at a conversion price of $1.00 per share, and pay cash to the Series B Holders equal to the difference between the 60-day VWAP and $3.00 per share, or (ii) pay cash to the Series B Holders equal to $3.00 per share.    
Series B Holders [Member]          
Entity Listings [Line Items]          
Share issued price $ 3.00   $ 3.00    
Preferred stock, conversion price 3.00   $ 3.00    
Series C Convertible Preferred Stock [Member] | Minimum [Member]          
Entity Listings [Line Items]          
Outstanding percentage   50.00%      
Exchange Agreement [Member] | Two Institutional Shareholders [Member] | Series B Convertible Preferred Stock [Member]          
Entity Listings [Line Items]          
Stock Issued During Period Shares Exchanged     4,908,333    
Share issued price $ 3.00   $ 3.00    
Treasury stock per share value     $ 3.00    
Securities Purchase Agreement [Member] | Hadron Healthcare Master Fund [Member]          
Entity Listings [Line Items]          
Share issued price   $ 3.70   $ 3.70  
Stock Issued During Period, Value, New Issues   $ 23,000,000.0      
Warrants and Rights Outstanding, Term   4 years   4 years  
Securities Purchase Agreement [Member] | Hadron Healthcare Master Fund [Member] | Maximum [Member]          
Entity Listings [Line Items]          
Number of shares exchanged value   $ 46,000,000.0